ArticlePloS one2025
Predicting the influence of homologous recombination repair deficiency genes on glioma heterogeneity and patient prognosis using multi-omics analysis and machine learning.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioma is the most common malignant tumor of the central nervous system, and homologous recombination deficiency (HRD) may play a crucial role in its progression. Our study aimed to predict the impact of HRD on glioma heterogeneity and patient prognosis from a multi-omics perspective.
methodsWe integrated HRD-related gene expression levels and survival information from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases. Using a combination of machine learning algorithms, we identified the optimal algorithm and constructed the HRD Index model. After validating the model's accuracy, we assessed the expression heterogeneity of HRD-related genes in vitro using quantitative polymerase chain reaction (qPCR). Multiple omics analyses, including enrichment analysis, genomics, prediction of immune cell subtype infiltration, and drug sensitivity, were employed to demonstrate the heterogeneity and clinical predictive significance of the HRD Index in glioma.
resultsThrough algorithm selection, the LASSO-RSF (Least Absolute Shrinkage and Selection Operator - Random Survival Forest) algorithm identified 7 genes (POLR2F, FANCB, PTEN, PLK3, INO80D, PRMT6, and UNG) to construct the HRD Index. Model validation demonstrated excellent accuracy. qPCR results revealed differential expression of these HRD Index genes among different cell lines. Samples grouped by HRD Index showed potential differences in certain cytokine and receptor pathways, as well as varying gene mutation frequencies between groups. Drug sensitivity analysis indicated that the HRD Index could predict treatment efficacy for specific drugs.
conclusionOur HRD Index model based on these seven genes significantly correlated with clinical prognosis in glioma patients and holds promise for guiding clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.